Prostate cancer · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ADT and Apalutamide Variant #01 Partial | — | R 1 206 | — | — | 73.9 mo | 1 | R 1 206 PFS proxy | 2 |
ADT and Darolutamide Variant #01 Partial | — | R 1 089 | 28d | — | — | 2 | R 2 179 PFS proxy | 1 |
ADT and Enzalutamide Variant #01 Partial | — | R 519 | — | 17.6 mo | 33.7 mo | 1 | R 519 PFS proxy | 8 |
ADT Variant #01 Partial | — | — | — | — | 52.0 mo | 1 | — | 14 |
4 of 4 regimens shown